Drugs & Aging

, Volume 28, Issue 12, pp 935–941 | Cite as

Choice of Long-Acting Insulin Therapy for Type 2 Diabetes

How Can Treatment for Older People be Optimized?


  1. 1.
    Evans A, Krentz AJ. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus. Drug Safety 1999; 21: 7–22PubMedCrossRefGoogle Scholar
  2. 2.
    Dominguez LJ, Paolisso G, Barbagallo M. Glucose control in the older patient: from intensive, to effective and safe. Aging Clin Exp Res 2010; 22: 274–80PubMedGoogle Scholar
  3. 3.
    Sinclair AJ, Conroy SP, Bayer AJ. Impact of diabetes on physical function in older people. Diabetes Care 2008; 31: 233–5PubMedCrossRefGoogle Scholar
  4. 4.
    Chen LK, Chen YM, Lin MH, et al. Care of elderly patients with diabetes mellitus: a focus on frailty. Ageing Res Rev 2010; 9Suppl. 1: S18–22PubMedCrossRefGoogle Scholar
  5. 5.
    Paolisso G. Pathophysiology of diabetes in elderly people. Acta Biomed 2010; 1Suppl. 1: 47–53Google Scholar
  6. 6.
    DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 2003; 26: 61–9CrossRefGoogle Scholar
  7. 7.
    Currie CJ, Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med 2010; 27: 938–48PubMedCrossRefGoogle Scholar
  8. 8.
    Gale EA. Diabetes in the UK: time for a reality check? Diabet Med 2010; 27: 973–6PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen D, Carter P. How small changes led to big profits for insulin manufacturers. BMJ 2010; 341: c7139PubMedCrossRefGoogle Scholar
  10. 10.
    Type 2 diabetes: newer agents (partial update of CG66). NICE [online]. Available from URL: http://www.nice.org.uk/CG87 Accessed 2011 May 29]
  11. 11.
    Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174–83PubMedCrossRefGoogle Scholar
  12. 12.
    Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–6PubMedCrossRefGoogle Scholar
  13. 13.
    Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009; 52: 1778–88PubMedCrossRefGoogle Scholar
  14. 14.
    Heller SR. Hypoglycaemia in type 2 diabetes. Diabetes Res Clin Pract 2008; 82Suppl. 2: S108–11PubMedCrossRefGoogle Scholar
  15. 15.
    Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736–47PubMedCrossRefGoogle Scholar
  16. 16.
    Unnikrishnan AG, Tibaldi J, Hadley-Brown M, et al. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract 2009; 63: 1571–7PubMedCrossRefGoogle Scholar
  17. 17.
    Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007 Apr 18; (2): CD005613Google Scholar
  18. 18.
    Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab 2009; 11: 53–9PubMedCrossRefGoogle Scholar
  19. 19.
    Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008; 149: 549–59PubMedGoogle Scholar
  20. 20.
    Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59PubMedCrossRefGoogle Scholar
  21. 21.
    Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–39PubMedCrossRefGoogle Scholar
  22. 22.
    Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699–708PubMedCrossRefGoogle Scholar
  23. 23.
    Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52:1971–3PubMedCrossRefGoogle Scholar
  24. 24.
    Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17–30PubMedCrossRefGoogle Scholar
  25. 25.
    Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocrine Practice 2009; 15: 540–59PubMedGoogle Scholar
  26. 26.
    Sinclair AJ. A report of the European Diabetes Working Party for Older People (EDWPOP): diabetes and metabolism. Amsterdam: Elsevier. In pressGoogle Scholar
  27. 27.
    Marouf E, Sinclair AJ. Use of short-acting insulin aspart in managing older people with diabetes. Clin Interv Aging 2009; 4: 187–90PubMedGoogle Scholar
  28. 28.
    Fonseca V, Davidson J, Home P, et al. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin 2010; 26: 1621–8PubMedCrossRefGoogle Scholar
  29. 29.
    Werner H, Weinstein D, Yehezkel E, et al. Controversies in the use of insulin analogues. Expert Opin Biol Ther 2011; 11: 199–209PubMedCrossRefGoogle Scholar
  30. 30.
    Prescribing for diabetes in England 2005/06 to 2010/11. NHS, 2011 Aug 24 [online]. Available from URL: http://www.ic.nhs.uk/pubs/prescribingfordiabetes05-11 [Accessed 2011 Aug 26]
  31. 31.
    Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009; 180: 400–7PubMedCrossRefGoogle Scholar
  32. 32.
    Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009; 7: 324–42PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Institute of Diabetes for Older People, Bedfordshire and Hertfordshire Postgraduate Medical SchoolUniversity of BedfordshireLutonUK

Personalised recommendations